The signature program: Bringing the protocol to the patient

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 2, 2015, Pages 124-126

  Kang, B P ^a   Slosberg, E ^a   Snodgrass, S ^a   Lebedinsky, C ^a   Berry, D A ^b   Corless, C L ^c   Stein, S ^a   Salvado, A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; GENOMICS; HUMAN; HUMAN GENOME; MOLECULAR BIOLOGY; ONCOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; ALGORITHM; CLINICAL PATHWAY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; METHODOLOGY; NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROGRAM DEVELOPMENT;

TUMOR MARKER;

ALGORITHMS; CRITICAL PATHWAYS; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROGRAM DEVELOPMENT; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 84943364767     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.126     Document Type: Article

References (5)

1. Redig, A.J. & Janne, P.A. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J. Clin. Oncol. 33, 975-977 (2015).
2. Giles, F., et al. The signature program, a distinctive tissue agnostic trial model for molecularly pre-selected hematological and solid tumor patients [abstract 4818]. Blood 124, 4818 (2014).
3. Lamberti, M.J., Brothers, C., Manak, D. & Getz, K. Benchmarking the study initiation process. Ther. Innovat. Regul. Sci. 47, 101-109 (2013).
4. Berry, S.M., Broglio, K.R., Groshen, S. & Berry, D.A. Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials. Clin. Trials 10, 720-734 (2013).
5. Steensma, D.P. & Kantarjian, H.M. Impact of cancer research bureaucracy on innovation, costs, and patient care. J. Clin. Oncol. 32, 376-378 (2014).